L. Nakashima

发表

Advising Cancer Patients on Natural Health Products— A Structured Approach

M. D. de Lemos, Leela John, L. Nakashima, 2004, The Annals of pharmacotherapy.

A retrospective review of gemcitabine use in advanced epithelial ovarian cancer

K. Swenerton, L. Nakashima, S. Spina, 1999 .

A real-world data approach to determine the optimal dosing strategy for pembrolizumab

Tonya Ng, L. Nakashima, K. Schaff, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Evolution of cancer treatment and evolving challenges

L. Nakashima, 2018, Healthcare management forum.

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.

K. Gelmon, D. Ayers, A. Tolcher, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines for the treatment of hypercalcemia associated with malignancy

L. Nakashima, 1997 .

A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.

K. Gelmon, D. Ayers, A. Tolcher, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.

D. Osoba, M. Fitch, D. Warr, 1995, The Canadian journal of oncology.

Barriers and facilitators for the safe handling of antineoplastic drugs

D. Brenner, M. Koehoorn, C. McLeod, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Significant hypersensitivity with paclitaxel managed by a 50 hour infusion

K. Swenerton, L. Nakashima, O. Keller, 1995 .

Occupational Exposure to Antineoplastic Drugs: Identification of Job Categories Potentially Exposed throughout the Hospital Medication System

K. Teschke, S. Venners, C. Hon, 2011, Safety and health at work.

Real-world incidence of venetoclax toxicities in British Columbia

A. Gerrie, M. D. de Lemos, L. Nakashima, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions

M. D. de Lemos, Esin Aysel Kandemir, L. Nakashima, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.

M. D. de Lemos, L. Nakashima, S. Yeung, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.